COX-2-selective NSAIDs and risk of hip or knee replacements: A population-based case-control study

Calcified Tissue International

Volumn 91, Issue 6, 2012, Pages 387-394

  Klop, Corinne ^a   De Vries, Frank ^a,b,c,d   Lalmohamed, Arief ^a   Mastbergen, Simon C ^e   Leufkens, Hubert G M ^a   Van Der Laan, Willemijn H Noort ^e,f   Bijlsma, Johannes W J ^e   Welsing, Paco M J ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f Department of Rheumatology ^*  (Netherlands)

Author keywords

Cyclooxygenase 2 selective inhibitor; Epidemiology; Hip replacement; Knee replacement; NSAID; Osteoarthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; GENDER; HIP ARTHROPLASTY; HIP OSTEOARTHRITIS; HUMAN; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OSTEOARTHRITIS; RISK;

EID: 84871237218     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9646-x     Document Type: Article

References (39)

1. Bijlsma JWJ, Berenbaum F, Lafeber FPJG (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377:2115-2126
2. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III. Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476-499
3. Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology 45:129-138
4. Zweers MC, de Boer TN, van Roon JAG, Bijlsma JWJ, Lafeber FPJG, Mastbergen SC (2011) Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther 13:239
5. El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH (2003) Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30:2444-2451
6. Mastbergen SC, Bijlsma JW, Lafeber FP (2005) Selective COX-2 inhibition is favorable to human early and late stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13:519-526
7. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP (2006) Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 8:R2
8. Blot L, Marcelis A, Devogelaer JP, Manicourt DH (2000) Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 131:1413-1421
9. Mastbergen SC, Marijnissen AC, Vianen ME, Zoer B, Roermund PM, Bijlsma JW, Lafeber FP (2006) Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology 45:405-413
10. Fukai A, Kamekura S, Chikazu D, Nakagawa T, Hirata M, Saito T et al (2012) Lack of chondroprotective effect of cyclooxygenase-2 inhibition in a mouse surgical osteoarthritis model. Arthritis Rheum 64:198-203
11. de Boer TN, Huisman AM, Polak AA, Niehoff AG, van Rinsum AC, Saris D et al (2009) The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis Cartilage 17:482-488
12. de Boer TN, Mastbergen SC, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP (2010) Lack of disease modifying activity of celecoxib in end-stage OA: a randomized controlled trial. Osteoarthritis Cartilage 18(Suppl 2):S145
13. Tindall EA, Sharp JT, Burr A, Katz TK, Wallemark CB, Verburg K et al (2002) A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 24:2051-2063
14. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL et al (2008) The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 58:3183-3191
15. Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Choquette D et al (2010) An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum 40:185-192
16. Ding C, Cicuttini F, Jones G (2009) Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am J Med 122:836-842
17. Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM (2005) Is there an association between the use ofdifferent types of nonsteroidal anti-inflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 52:3137-3142
18. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F (1989) Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 2:519-522
19. Herings RMC (2007) The PHARMO System. CNS Spectr 12:9 Suppl 16:14-17. http://www.primarypsychiatry.com/aspx/articledetail.aspxarticleid=1826. Accessed on 6 Aug 2012
20. de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O et al (2008) Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. J Hypertens 26:124-129
21. Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2011) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int 22:2197-2204
22. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H et al (2008) Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 65:580-586
23. Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG et al (2010) Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab 95:1924-1931
24. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22:903-910
25. van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C et al (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705-1713
26. SAS/STAT 9.2 user's guide, 2nd ed. Example 64.5 Conditional logistic regression for m:n matching. http://support.sas.com/documentation/cdl/en/statug/ 63033/HTML/default/viewer.htm#statug-phreg-sect036.htm. Accessed on 9 Aug 2012
27. Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356-365
28. Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T et al (2009) Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke 40:3281-3285
29. Rolfson O, Kǎrrholm J, Dahlberg LE, Garellick G (2011) Patientreported outcomes in the Swedish Hip Arthroplasty Register -results of a nationwide prospective observational study. J Bone Joint Surg Br 93:867-875
30. Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E (2011) Summary and recommendations of the OARSI FDA Osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 19:606-610
31. Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Colvo E, Hernandez M et al (2006) Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 65:998-1005
32. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J et al (2008) Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 16:1484-1493
33. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D et al (2002) Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46:1789-1803
34. Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577-581
35. MacDonald TM, Pettitt D, Lee FH, Schwartz JS (2003) Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology 42:3-10
36. Zhao SZ, Wentworth C, Burke TA, Makuch RW (2004) Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 13:277-287
37. van der Schee E, van Dijk L, Blom L, Lelie-van der Zande R, Broerse A (2004) Medicatiebewaking rond recept -en zelfzorggeneesmiddelen. Consumentenpanel Gezondheidszorg peilt leemtes. Pharm Weekbl 139:618-622
38. Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP (2010) Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am 92:2156-2164
39. National Joint Registry for England and Wales (2011) NJR 8th annual report. www.njrcentre.org.uk. Accessed on 25 July 2012